GLP-1 medications and bariatric surgery are not always mutually exclusive
Using data from over 45 million de-identified patient records, the team found that more than 870,000 people were prescribed a GLP-1RA between 2011 and 2023
And this is what it does in there - Slows how quickly food leaves your stomach, making you feel full for longer Flattens the sugar spike in your blood by reducing the rate at which glucose enters your body Feeds beneficial gut bacteria that produce short-chain fatty acids, including butyrate This is why the EFSA has authorised the health claim: Beta-glucan contributes to the maintenance of normal blood cholesterol levels and to weight management as part of a calorie-restricted diet
When combined with the slowed digestion of semaglutide, this can lead to significant discomfort and a risk of dehydration
They serve different clinical purposes and cannot substitute for each other
Furthermore, emerging studies explore its combined effects with GLP-1 receptor agonists in controlled models